These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185 [TBL] [Abstract][Full Text] [Related]
8. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
9. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803 [TBL] [Abstract][Full Text] [Related]
10. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines. Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638 [TBL] [Abstract][Full Text] [Related]
12. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298 [TBL] [Abstract][Full Text] [Related]
13. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699 [TBL] [Abstract][Full Text] [Related]
14. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591 [TBL] [Abstract][Full Text] [Related]
15. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342 [TBL] [Abstract][Full Text] [Related]
16. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921 [TBL] [Abstract][Full Text] [Related]